UBS Group’s Boston Scientific BSX Stock Holding History

UBS Group’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.3M	Sell	259,700 -119,600	-32%	-$9.57M	﹤0.01%	2818
2025 Q4	$36.2M	Buy	379,300 +249,300	+192%	+$24.4M	0.01%	1982
2025 Q3	$12.7M	Sell	130,000 -99,800	-43%	-$10.3M	﹤0.01%	3034
2025 Q2	$24.7M	Buy	229,800 +7,600	+3%	+$769K	﹤0.01%	2156
2025 Q1	$22.4M	Sell	222,200 -193,200	-47%	-$19.5M	﹤0.01%	2200
2024 Q4	$37.1M	Buy	415,400 +38,400	+10%	+$3.38M	0.01%	1727
2024 Q3	$31.6M	Buy	377,000 +61,400	+19%	+$4.84M	0.01%	1483
2024 Q2	$24.3M	Buy	315,600 +6,200	+2%	+$454K	0.01%	1526
2024 Q1	$21.2M	Hold	309,400	–	–	0.01%	1638
2023 Q4	$17.9M	Hold	309,400	–	–	0.01%	1656
2023 Q3	$16.3M	Buy	309,400 +98,500	+47%	+$5.17M	0.01%	1628
2023 Q2	$11.4M	Buy	210,900 +112,400	+114%	+$5.87M	﹤0.01%	1869
2023 Q1	$4.93M	Sell	98,500 -278,800	-74%	-$13.1M	﹤0.01%	2538
2022 Q4	$17.5M	Sell	377,300 -170,200	-31%	-$7.37M	0.01%	1513
2022 Q3	$21.2M	Sell	547,500 -489,500	-47%	-$19.6M	0.01%	1236
2022 Q2	$38.6M	Buy	1,037,000 +505,800	+95%	+$20.6M	0.02%	881
2022 Q1	$23.5M	Sell	531,200 -319,700	-38%	-$13.9M	0.01%	1307
2021 Q4	$36.1M	Buy	850,900 +120,185	+16%	+$5.05M	0.01%	1163
2021 Q3	$31.7M	Sell	730,715 -245,385	-25%	-$10.9M	0.01%	1137
2021 Q2	$41.7M	Buy	976,100 +276,700	+40%	+$11.6M	0.01%	965
2021 Q1	$27M	Buy	699,400 +158,700	+29%	+$6.01M	0.01%	1228
2020 Q4	$19.4M	Sell	540,700 -6,000	-1%	-$216K	0.01%	1364
2020 Q3	$20.9M	Sell	546,700 -380,400	-41%	-$14.7M	0.01%	1142
2020 Q2	$32.6M	Buy	927,100 +5,900	+0.6%	+$212K	0.01%	806
2020 Q1	$30.1M	Buy	921,200 +913,700	+12,183%	+$35.7M	0.01%	776
2019 Q4	$339K	Buy	7,500 +4,600	+159%	+$192K	﹤0.01%	5185
2019 Q3	$118K	Sell	2,900 -103,900	-97%	-$4.4M	﹤0.01%	5663
2019 Q2	$4.59M	Buy	106,800 +105,500	+8,115%	+$4.06M	﹤0.01%	2397
2019 Q1	$50K	Sell	1,300 -61,200	-98%	-$2.34M	﹤0.01%	5546
2018 Q4	$2.21M	Buy	62,500 +56,400	+925%	+$2.05M	﹤0.01%	2937
2018 Q3	$235K	Buy	6,100 +5,100	+510%	+$178K	﹤0.01%	4935
2018 Q2	$33K	Sell	1,000 -9,500	-90%	-$287K	﹤0.01%	6307
2018 Q1	$287K	Buy	+10,500	New	+$285K	﹤0.01%	4542
2017 Q4	–	Sell	-9,300	Closed	-$271K	–	7844
2017 Q3	$271K	Buy	9,300 +6,800	+272%	+$188K	﹤0.01%	4653
2017 Q2	$70K	Sell	2,500 -8,000	-76%	-$212K	﹤0.01%	5409
2017 Q1	$261K	Sell	10,500 -128,200	-92%	-$3.12M	﹤0.01%	4476
2016 Q4	$3M	Sell	138,700 -47,000	-25%	-$1.03M	﹤0.01%	2544
2016 Q3	$4.42M	Hold	185,700	–	–	﹤0.01%	2133
2016 Q2	$4.34M	Buy	185,700 +184,700	+18,470%	+$4M	﹤0.01%	2065
2016 Q1	$19K	Buy	1,000 +800	+400%	+$14.1K	﹤0.01%	6230
2015 Q4	$4K	Sell	200 -1,000	-83%	-$17.9K	﹤0.01%	7759
2015 Q3	$19K	Buy	1,200 +1,000	+500%	+$17.1K	﹤0.01%	6736
2015 Q2	$4K	Sell	200 -200	-50%	-$3.57K	﹤0.01%	7955
2015 Q1	$7K	Sell	400 -103,100	-100%	-$1.63M	﹤0.01%	7889
2014 Q4	$1.37M	Buy	+103,500	New	+$1.32M	﹤0.01%	3291

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group's BSX Position: Q1 2026 in Review

UBS Group reduced its Boston Scientific (BSX) stake by 0.32% in Q1 2026, selling an estimated $3.8M and leaving 14,824,662 shares worth $930M. The position accounts for 0.14% of the portfolio, ranked #145.

UBS Group first reported a position in BSX in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.42B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

UBS Group held 14,824,662 shares of Boston Scientific worth $930M as of Q1 2026.
UBS Group sold 47,464 Boston Scientific shares in Q1 2026, an estimated $3.8M.
Boston Scientific made up 0.14% of UBS Group's portfolio in Q1 2026, its #145 holding.
UBS Group first reported a position in Boston Scientific in Q4 2014 and has held it in 46 quarters since.
UBS Group's Boston Scientific position peaked at $1.42B in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.